Diabetes
« Previous EntriesDART effective for weight loss in schizophrenia patients with Type 2 diabetes
Wednesday, August 18th, 2010Source: MedWire News
A 24-week dietary and lifestyle intervention program has been shown to result in significant reductions in body mass index (BMI) and weight and improve diabetes knowledge of schizophrenia patients with Type 2 diabetes.
Previous research has shown that people with schizophrenia are about twice as likely to develop diabetes as the general population, […]
Retinopathy prevalence high in US adults with diabetes
Thursday, August 12th, 2010Source: MedWire News
Over a quarter of US diabetics aged 40 years or older have retinopath, with a particularly high prevalence seen in non-Hispanic Black individuals, show study results published in the Journal of the American Medical Association.
“Investigating the prevalence of diabetic retinopathy (DR) is important because it is a key indicator of systemic diabetic microvascular […]
Exenatide treatment improves adiponectin and CRP levels
Wednesday, August 4th, 2010Source: MedWire News
Treatment with the oral hypoglycemic drug exenatide has beneficial effects on adiponectin and C-reactive protein (CRP) levels, suggest study findings published in the journal Diabetes Care.
These findings provide further evidence for the benefits of treatment with exenatide, adding to previous results demonstrating its potential for reducing body weight and improving glycemic control.
Mathijs Bunck […]
Candesartan shows potential for preserving insulin secretion
Tuesday, August 3rd, 2010Source: MedWire News
Japanese research has revealed that candesartan may act against pancreatic β-cell lipotoxicity, suggesting it could have potential in preserving insulin secretion in patients with Type 2 diabetes.
The angiotensin receptor blocker (ARB) suppressed fatty acid-induced oxidative stress and the activation of nicotinamide adenine dinucleotide phosphate (NAD[P]H) oxidase in pancreatic β mouse cells, the researchers […]
FDA Panel Votes To Keep Avandia On Market With More Restrictions.
Thursday, July 15th, 2010ABC World News (7/14, story 5, 0:25, Sawyer) reported, “A surprise decision on Avandia [rosiglitazone]. Advisers to the Food and Drug Administration recommended keeping Avandia on the market,” although most “advisers did recommend stricter warning labels and the FDA will now decide which course to take.”
The […]
